Please login to the form below

Not currently logged in
Email:
Password:

CMA

This page shows the latest CMA news and features for those working in and with pharma, biotech and healthcare.

Concordia accused of overcharging NHS for thyroid drug

Concordia accused of overcharging NHS for thyroid drug

Markets Authority (CMA), which says Concordia “abused its dominant position to overcharge the NHS”. ... Concordia said it is “working to better understand the CMA's position and will continue to work constructively to resolve these matters”.

Latest news

  • MSD probed by UK for blocking Remicade biosimilars MSD probed by UK for blocking Remicade biosimilars

    The Competition and Markets Authority (CMA) issued a ‘statement of objections’against the pharma company - known as Merck &Co in North America - saying that the discount scheme for Remicade (infliximab) was ... The action is the latest in a series

  • EU starts investigation of Aspen's cancer drug pricing EU starts investigation of Aspen's cancer drug pricing

    Last December, Pfizer was fined £84m by the Competitions and Markets Authority (CMA) for conspiring with Flynn Pharma to raise the price of epilepsy drug phenytoin, and the CMA has since

  • Pfizer gets record £84m fine for hiking price of epilepsy drug Pfizer gets record £84m fine for hiking price of epilepsy drug

    US firm plans to appeal after CMA finds it raised NHS fee by 2, 600% in 2012. ... The Competition and Markets Authority (CMA) has levied an £84.2m fine on Pfizer - as well as a £5.2m penalty for distributor Flynn Pharma - saying they hiked the price of

  • UK government fines GSK over 'pay-for-delay' deals UK government fines GSK over 'pay-for-delay' deals

    The CMA's decision relates to activities between 2001 and 2004 in which GSK agreed to pay £50m to companies supplying generic versions of Seroxat (paroxetine) in order to delay their ... GSK says it rejects the CMA's interpretation of the events. In a

  • Pfizer and Flynn accused of overcharging for epilepsy drug Pfizer and Flynn accused of overcharging for epilepsy drug

    By 2013, the cost to the NHS had rocketed up to £50m, says the CMA in a 'statement of objections' released yesterday. ... Businesses are generally free to set prices as they see fit," said Ann Pope, the CMA's senior director of antitrust enforcement.

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics